Answer
They are antibodies that neutralise factor VIII and can make replacement treatment less effective. They are assessed through clinical response and laboratory testing.
Sources for this answer
- Haemoctin 1000 — Current selected SmPCemc · Summary of Product Characteristics
- Optivate powder and solvent for solution for injection — Current selected SmPCemc · Summary of Product Characteristics